You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (0) |
Back to Search
EFFICACY AND SAFETY OF 12-WEEK LEDIPASVIR/SOFOSBUVIR IN PATIENTS WITH CHRONIC HEPATITIS C
- At: AbuDhabi (United Arab Emirates) (2019)
- Type: Poster
- Poster code: POS-HPS-077
- By: LIU, Min-Li (E-Da Cancer Hospital, Department of Pharmacy, China Taiwan)
- Co-author(s): Min-Li Liu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
Yung-Chia Hsu: Department of Pharmacy, E-Da Cancer Hospital, Kaohsiung, China Taiwan
Yi-Ping Hsiang: Department of Pharmacy, E-Da Hospital, Kaohsiung, China Taiwan - Abstract:
Background
Direct-acting antiviral agents, including ledipasvir (LDV)/sofosbuvir (SOF), are now novel therapeutic agents for chronic hepatitis C (CHC). However, the efficacy and safety of these agents is not fully explored in Taiwan.
Methods
Patients with CHC receiving LDV/SOF 90 mg/400 mg with or without ribavirin for 12 weeks in our hospital from
.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026